$11.23
0.97% today
Nasdaq, Sep 30, 04:50 pm CET

10x Genomics Inc - Ordinary Shares - Class A Stock price

$11.34
-2.67 19.06% 1M
+2.61 29.90% 6M
-3.02 21.03% YTD
-11.24 49.78% 1Y
-18.59 62.11% 3Y
-113.63 90.93% 5Y
-41.41 78.50% 10Y
-41.41 78.50% 20Y
Nasdaq, Closing price Mon, Sep 29 2025
-0.38 3.24%

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$964.5m
Net debt
positive
Cash
$447.3m
Shares outstanding
124.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.2 | 2.3
EV/Sales
1.5 | 1.5
EV/FCF
17.0
P/B
1.8
Financial Health
Equity Ratio
77.3%
Return on Equity
-25.7%
ROCE
-17.3%
ROIC
-34.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$644.5m | $623.9m
EBITDA
$-105.4m | $-76.5m
EBIT
$-150.4m | $-81.7m
Net Income
$-84.6m | $-75.1m
Free Cash Flow
$56.9m
Growth (TTM | estimate)
Revenue
2.0% | 2.2%
EBITDA
51.2% | 48.5%
EBIT
40.6% | 57.5%
Net Income
64.7% | 58.9%
Free Cash Flow
270.0%
Margin (TTM | estimate)
Gross
69.5%
EBITDA
-16.4% | -12.3%
EBIT
-23.3%
Net
-13.1% | -12.0%
Free Cash Flow
8.8%
More
EPS
$-0.7
FCF per Share
$0.5
Short interest
22.4%
Employees
1k
Rev per Employee
$470.0k
Show more

Is 10x Genomics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

10x Genomics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:

10x Buy
45%
12x Hold
55%

Analyst Opinions

22 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:

Buy
45%
Hold
55%

Financial data from 10x Genomics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
644 644
2% 2%
100%
- Direct Costs 197 197
12% 12%
31%
448 448
10% 10%
69%
- Selling and Administrative Expenses 340 340
2% 2%
53%
- Research and Development Expense 259 259
14% 14%
40%
-105 -105
51% 51%
-16%
- Depreciation and Amortization 45 45
21% 21%
7%
EBIT (Operating Income) EBIT -150 -150
41% 41%
-23%
Net Profit -85 -85
65% 65%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about 10x Genomics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

10x Genomics Inc - Ordinary Shares - Class A Stock News

Neutral
Seeking Alpha
20 days ago
10x Genomics, Inc. (NASDAQ:TXG ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Serge Saxonov - Co-Founder, CEO & Director Conference Call Participants Yih-Ming Tu - Morgan Stanley, Research Division Presentation Yih-Ming Tu Research Associate Good morning, everyone. Welcome to day 3 of the Morgan Stanley Global Healthcare Conference.
Neutral
PRNewsWire
21 days ago
Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path for Blood Disorder Diagnosis, complementing bone marrow procedures PLEASANTON, Calif. and REHOVOT, Israel , Sept.
Neutral
PRNewsWire
about one month ago
PLEASANTON, Calif. , Aug. 27, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, at 11:30 a.m.
More 10x Genomics Inc - Ordinary Shares - Class A News

Company Profile

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.

Head office United States
CEO Serge Saxonov
Employees 1,306
Founded 2012
Website www.10xgenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today